Biocon Ltd.
| BSE: 532523 | Sector: Health care |
| NSE: BIOCON | ISIN Code: INE376G01013 |
| BSE 00:00 | 04 Mar | 399.45 |
-3.35 (-0.83%) |
OPEN
400.00 |
HIGH
407.10 |
LOW
398.05 |
| NSE 00:00 | 04 Mar | 399.75 |
-2.95 (-0.73%) |
OPEN
399.00 |
HIGH
407.10 |
LOW
398.30 |
| OPEN | 400.00 |
| PREVIOUS CLOSE | 402.80 |
| VOLUME | 163302 |
| 52-Week high | 487.70 |
| 52-Week low | 235.80 |
| P/E | 162.38 |
| Mkt Cap.(Rs cr) | 47,934 |
| Buy Price | 399.45 |
| Buy Qty | 3.00 |
| Sell Price | 399.45 |
| Sell Qty | 751.00 |
Biocon Ltd. (BIOCON) - Latest News & Headlines
-
Stocks to watch: Stove Kraft, Hero Moto, Britannia, M&M, Biocon, Tata Power
8.24 am | 5 Feb 2021 | Business Standard
IRFC has sold $750 million worth of dollar-denominated bonds to overseas investors priced at a coupon of just 2.80 per cent per annum
-
Biocon stock slides on poor Q3 results, exit of biologics arm's MD
12.44 am | 23 Jan 2021 | Business Standard
From its previous close of Rs 441.95 apiece on Thursday, the stock closed 10.89 per cent or Rs 48.15 lower at Rs 393.80, on Friday
-
Market reacts negatively to Biocon's weaker results, exit of biologics' MD
1.15 pm | 22 Jan 2021 | Business Standard
Analysts have raised doubts over the $1 billion guidance for biosimilars by FY22 and Hamacher's exit due to "professional differences"
-
Biocon tanks 10% on lower-than-expected December quarter results
10.26 am | 22 Jan 2021 | Business Standard
Due to professional differences with the chairperson on strategic priorities and the vision for the company, Dr Christiane Hamacher has stepped down a...
-
Biocon posts 19% dip in Q3 net profit as generics biz takes a hit
1.00 am | 22 Jan 2021 | Business Standard
Biocon's consolidated revenue for Q3 of FY21 increased by 7.20 per cent at Rs 1878.9 crore as against Rs 1752.6 crore for the said quarter last year
-
Bright outlook: Sun Pharma to Cipla, drug firms set for Q3 health boost
1.11 am | 11 Jan 2021 | Business Standard
Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportuni...
-
Biocon gains 2% after arm gets Rs 555 crore capital injection from ADQ
9.46 am | 8 Jan 2021 | Business Standard
ADQ will invest Rs 555 Crore for a 1.80 per cent minority stake in the biosimilar business, valuing Biocon Biologics at a post money valuation of arou...
-
Stocks to watch: TCS, Biocon, Bharat Rasayan, Vodafone Idea, Tata Power
8.39 am | 8 Jan 2021 | Business Standard
Biocon announced that its subsidiary Biocon Biologics has approved a primary equity investment by Abu Dhabi-based ADQ, one of the region's largest hol...
-
Three stocks that Nilesh Jain of Anand Rathi Shares is bullish on
7.30 am | 1 Jan 2021 | Business Standard
The stock of Hindustan Petroleum Corporation (HPCL) has formed a strong base at around 205 levels and is making a higher top and higher bottom formati...
-
Indices gain for 5th straight day, Sensex ends 259 pts up; banks outperform
3.59 pm | 29 Dec 2020 | Business Standard
All that happened in the markets today
-
Stocks to watch: Wipro, 3i Infotech, Biocon, SBI Life, AU Small Finance
8.51 am | 29 Dec 2020 | Business Standard
3i Infotech Ltd has entered into definitive agreements to sell its software products business to the funds advised by Apax Partners for Rs 1,000 crore
-
Biocon: Street to keep an eye on CY21 launches, market share gains
12.27 am | 29 Dec 2020 | Business Standard
Launch of a cancer drug was delayed due to Covid-19
-
Nifty outlook and stock recommendations by Sameet Chavan of Angel Broking
8.34 am | 28 Dec 2020 | Business Standard
If Nifty again slide below 13,626, we may see some corrective move in the concluding week of the current calendar year
-
Biocon dips 11% in three days on disappointing September quarter results
2.58 pm | 26 Oct 2020 | Business Standard
The company said profitability was impacted on account of higher R&D expenses, staff costs, other expenses and forex losses
-
Biocon posts 22% fall in Q2 net profit on high R&D expenses, staff costs
1.11 am | 24 Oct 2020 | Business Standard
The Bengaluru-headquartered company posted 10 per cent growth in consolidated revenue on a y-o-y basis to Rs 1,760 crore in Q2
-
Strong prospects of Biologics business keep Street positive on Biocon
10.24 pm | 23 Oct 2020 | Business Standard
Even though Q2 performance missed estimates, analysts expect a stronger second half
-
Sales of Biocon's itolizumab surge as phase-4 clinical trials begin
1.04 am | 6 Oct 2020 | Business Standard
With phase 4 clinical trials now on, the sales may see a further uptick if data supports its use on Covid-19 patients, said experts.
-
Covid-19: We need a shift to sustainability, says Kiran Majumdar-Shaw
1.34 am | 5 Oct 2020 | Business Standard
The pandemic has thrown us into the deep end in terms of using technology, and that is a positive development, says Shaw
-
Dr Reddy's, Biocon, Torrent Pharma: What charts indicate for these stocks
12.01 pm | 17 Sep 2020 | Business Standard
The next upside for Nifty Pharma is located above the resistance of 12,100 levels.
-
Biocon set for bigger insulin play, aims to reach one in five diabetics
11.12 am | 7 Sep 2020 | Business Standard
Biocon Biologics CEO says portfolio to form a substantial part of $1 bn revenue target, to roll out insulin Aspart by next year
Quick Links for Biocon:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
